Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04802746 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

A Phase 1 study of Healthy Study Participants and Participants With Mild Asthma, sponsored by UCB Biopharma SRL.

Completed
Registry status
Phase 1
Development phase
78
Enrollment target
2
Study locations

NCT04802746 is a Phase 1 study of Healthy Study Participants and Participants With Mild Asthma that has completed, run by UCB Biopharma SRL. The registered enrollment target is 78 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04802746, a Phase 1 study of Healthy Study Participants and Participants With Mild Asthma, has completed, sponsored by UCB Biopharma SRL.

COMPLETED
Registry status
Phase 1
Development phase
78 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the study is to assess the pulmonary safety of Staccato alprazolam in healthy study participants and in and study participants with mild asthma

Interventions

  • OTHER Placebo
  • DRUG Alprazolam

Study Locations (2)

Massachusetts

  • Up0099 101 - North Dartmouth

North Carolina

  • Up0099 102 - Raleigh

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2021-03-09
Est. Completion 2021-11-22
Phase Phase 1

Sponsor

UCB Biopharma SRL

82 total trials

What the Registry Record Tells You About NCT04802746

The ClinicalTrials.gov registry entry for NCT04802746 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy Study Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04802746 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, North Carolina.

Frequently Asked Questions

What is clinical trial NCT04802746 about?

NCT04802746 is a clinical study titled "A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma". The purpose of the study is to assess the pulmonary safety of Staccato alprazolam in healthy study participants and in and study participants with mild asthma

What is the current status of trial NCT04802746?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2021-03-09. Estimated completion is 2021-11-22.

What conditions does trial NCT04802746 study?

This clinical trial studies the following conditions: Healthy Study Participants, Participants With Mild Asthma.

What interventions are being tested in trial NCT04802746?

The interventions under investigation include: Placebo (OTHER), Alprazolam (DRUG).

Who is sponsoring clinical trial NCT04802746?

This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04802746 being conducted?

This trial has 2 study locations across Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.